Product Details

Banzel

Rufinamide
200 mg
Tablet


DIN/PIN/NPN

02369621

Manufacturer

Eisai Limited

Formulary Listing Date

2025-01-31  

Unit Price

1.9047

Amount MOH Pays

1.0083

Coverage Status

Off-Formulary Interchangeable Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

N03AF03

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02369621 Banzel 1.9047 1.0083
02545985 Auro-Rufinamide 1.0083 1.0083
 

LU Clinical Criteria

NO  

EAP Criteria

Therapeutic Class Reimbursement Criteria
Anticonvulsants

Rufinamide

  • Brand(s): Banzel
  • Dosage Form/Strength: 100 mg, 200 mg, 400 mg

For the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients who meet the following criteria:

  • Patient is 4 years of age or older; AND

  • the Patient is currently on two or more anti-epileptic drugs (AEDs) without optimal seizure control; AND

  • the Patient has failed an adequate trial1 of lamotrigine AND topiramate; AND

  • the Patient is in the care of a physician experienced in managing seizures.

1If an adequate trial of lamotrigine and/or topiramate is not possible due to intolerance or contraindication, a less costly AED that is listed as a benefit on the Ontario drug benefit formulary must be tried in its place

Dose: Maximum daily dose is 1,300 mg per day for patients less than 30 kg; and 3,200 mg per day for patients 30 kg or greater

Exclusion Criteria:

Funding will not be approved for the following circumstances:

  • Banzel used first line for LGS; OR

  • Treatment of partial seizures

Duration of Approval: Lifetime

EAP Drug Request Form:

Standard Form for EAP Drug Requests

Product Monograph

View Monograph